Alvotech Announces Topline Results From Confirmatory Patient Study For AVT03, A Proposed Biosimilar For Prolia and Xgeva
Portfolio Pulse from Benzinga Newsdesk
Alvotech (NASDAQ:ALVO) announced positive topline results from a confirmatory patient study for AVT03, a proposed biosimilar to Prolia and Xgeva. The study met its primary endpoints, demonstrating clinical similarity in terms of efficacy, safety, immunogenicity, and pharmacokinetics. Alvotech plans to file marketing applications for AVT03 later this year.
July 02, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alvotech announced positive results from a study for AVT03, a proposed biosimilar to Prolia and Xgeva. The study met its primary endpoints, and Alvotech plans to file marketing applications later this year.
The positive study results and the plan to file marketing applications later this year are likely to boost investor confidence in Alvotech, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100